AI assistant
Crinetics Pharmaceuticals, Inc. — Director's Dealing 2020
Mar 27, 2020
31156_dirs_2020-03-27_dad59cf8-1aeb-4d35-8f4f-2f5e2c912e91.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2020-03-20
Reporting Person: Madan Ajay (Chief Development Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 76046 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $0.73 | 2026-05-26 | Common Stock (106383) | Direct | |
| Stock Option (right to buy) | $9.28 | 2028-05-24 | Common Stock (91185) | Direct | |
| Stock Option (right to buy) | $25.19 | 2029-03-07 | Common Stock (56250) | Direct | |
| Stock Option (right to buy) | $22.61 | 2030-02-23 | Common Stock (70000) | Direct |
Footnotes
F1: 25% of the shares subject to the option vested on July 17, 2017 and 1/48th of the total remaining number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. The shares subject to the option are also subject to accelerated vesting as set forth in the employment agreement between the Issuer and the Reporting Person.
F2: 1/48th of the shares subject to the option vested on June 25, 2018 and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. The shares subject to the option are also subject to accelerated vesting as set forth in the employment agreement between the Issuer and the Reporting Person.
F3: 1/48th of the shares subject to the option vested on April 8, 2019 and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. The shares subject to the option are also subject to accelerated vesting as set forth in the employment agreement between the Issuer and the Reporting Person.
F4: 1/48th of the shares subject to the option vested on March 24, 2020 and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. The shares subject to the option are also subject to accelerated vesting as set forth in the employment agreement between the Issuer and the Reporting Person.